--- title: "Altamira Therapeutics files Form 15 to end SEC reporting duties" url: "https://aibio.space/news/altamira-therapeutics-files-form-15-end-sec-reporting-duties/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2026-02-27" section: "Listings" tickers: "OTC:CYTOF" source: "https://www.sec.gov/Archives/edgar/data/1601936/000121390026021580/eaf1512g-1512g_altamira.htm" summary: "Altamira Therapeutics filed a Form 15 dated February 27, 2026, to terminate its registration or suspend its duty to file reports with the SEC. The form lis" --- By the aibio.space news desk. Sources - [Altamira Therapeutics Ltd. 15-12G (2026-02-27)](https://www.sec.gov/Archives/edgar/data/1601936/000121390026021580/eaf1512g-1512g_altamira.htm) - [Altamira Therapeutics Ltd. 20-F (2025-04-30): business](https://www.sec.gov/Archives/edgar/data/1601936/000121390025037199/ea0237996-20f_altamira.htm) - [Altamira Therapeutics Ltd. financial data (SEC XBRL)](https://www.sec.gov/Archives/edgar/data/1601936/000121390021018959/) [CYTOF](https://aibio.space/companies/altamira-therapeutics/) 2026-02-27 # Altamira Therapeutics files Form 15 to end SEC reporting duties Tickers [CYTOF](https://aibio.space/companies/altamira-therapeutics/) Altamira Therapeutics filed a Form 15 dated February 27, 2026, to terminate its registration or suspend its duty to file reports with the SEC. The form lists 48 holders of record, and the company's last business description, from April 2025, still calls its lead programs preclinical. ## Key facts - **Company**: Altamira Therapeutics Ltd. (OTC: CYTOF) - **News type**: Listings - **Primary source**: [Altamira Therapeutics Ltd. 15-12G (2026-02-27)](https://www.sec.gov/Archives/edgar/data/1601936/000121390026021580/eaf1512g-1512g_altamira.htm) *The Capitol dome seen from below. Photo: U.S. Department of Homeland Security (Source), CC0, via rawpixel. The picture shows the field, not the companies named.* Altamira Therapeutics Ltd. filed a Form 15 with the Securities and Exchange Commission dated February 27, 2026. The form is a certification and notice of termination of registration under Section 12(g) of the Securities Exchange Act of 1934, or a suspension of the duty to file reports under Sections 13 and 15(d). It covers the company's common shares, par value $0.002 per share, and lists no other class of securities for which a duty to file reports remains. The company marked two rule provisions as the basis for the filing: Rule 12g-4(a)(1) and Rule 12h-3(b)(1)(i). The form gives the approximate number of holders of record of the common stock as 48. It is signed by Thomas Meyer, chief executive officer, and lists the company's offices at Clarendon House, 2 Church Street, in Hamilton, Bermuda. The commission file number is 001-36582. The form does not give a reason for the filing. It does not describe the company's cash, its trading venue or any transaction that led to it. ## The business as described in April 2025 The company's annual report on Form 20-F, filed in April 2025, is the most recent business description available. It describes Altamira as a Bermuda exempted company that began its current operations in 2003. The company was called Auris Medical AG until 2014, when it became Auris Medical Holding AG, and it redomesticated to Bermuda in 2019. It took the name Altamira Therapeutics Ltd. in 2021. The report calls the company a preclinical-stage biopharmaceutical company developing peptide-based nanoparticle technology, called xPhore, for delivering RNA to tissues outside the liver. Its two flagship siRNA programs are AM-401 for KRAS-driven cancer, such as colorectal or pancreatic cancer, and AM-411 for rheumatoid arthritis. The report says both are in preclinical development beyond in vivo proof of concept. The company intends to take at least one program to an investigational new drug application or a Phase 1 trial before seeking to license it out. The report says the company spun off a 51% stake in Altamira Medica AG in 2023, which makes the Bentrio nasal spray, and that it keeps a 49% stake with additional economic rights. It also says the company intended to partner or divest its legacy assets in 2025. Those assets include AM-125, a nasal spray for vertigo described as post Phase 2, and programs in tinnitus and hearing loss. Any proceeds from those steps would go to the RNA delivery work. Capital expenditures were $0.1 million in 2024, $0 in 2023 and $2.1 million in 2022, according to the report, and the 2024 spending was mainly for production equipment. ## Older financial figures The financial data here comes from a 2021 annual report. It shows research and development expense of CHF 2.9 million for 2020, down from CHF 3.3 million for 2019. The net loss was CHF 8.2 million for 2020, against CHF 6.6 million for 2019. Those figures cover 2019 and 2020, years before the Form 15, and they say nothing about the company's current cash or losses. ## What the filing leaves open The 2025 report set a goal of partnering or divesting the legacy assets during 2025. The Form 15 does not say whether those steps happened. The report also described its lead programs as preclinical, and it gives no clinical results for them. The company's future reporting would depend on whether the Form 15 takes effect as the rules it cites provide, and the form does not discuss that. The number of holders, 48, is the only shareholder figure the filing gives. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story CYTOF Altamira Therapeutics Ltd. OTC ยท Bermuda Open the starter desk ## More in Listings Listings ### [Propanc Biopharma faces Nasdaq delisting on bid price, plans to appeal](https://aibio.space/news/propanc-biopharma-faces-nasdaq-delisting-bid-price-plans-appeal/) Oct 29, 2026 Listings ### [Reviva asks stockholders to approve reverse split of up to 1-for-100](https://aibio.space/news/reviva-asks-stockholders-approve-reverse-split-up-1-100/) Oct 29, 2026 Listings ### [Nasdaq to delist Glucotrack shares after bid price exception ends](https://aibio.space/news/nasdaq-delist-glucotrack-shares-after-bid-price-exception-ends/) Oct 28, 2026 --- Source page: https://aibio.space/news/altamira-therapeutics-files-form-15-end-sec-reporting-duties/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Altamira Therapeutics files Form 15 to end SEC reporting duties", 2026-02-27, https://aibio.space/news/altamira-therapeutics-files-form-15-end-sec-reporting-duties/